Illumina Launches Pilot Proteomics Program with UK Biobank and Industry Partners

NavDx Test Expands Availability for Enhanced Surveillance in HPV+ Anal Cancer Patients

QIAGEN Enhances QIAcuity Digital PCR with Expanded Multiplexing Capabilities

Boehringer Ingelheim Licenses Synaffix’s ADC Technology to Advance Cancer Therapies

AIG Hospitals to Launch ₹800 Crore Oncology Centre with South-East Asia’s First Dynamic ARC Proton Therapy

Qiagen Secures FDA Clearance for QIAstat-Dx Gastrointestinal Panel

Ovation.io Launches Groundbreaking GLP-1 Research Dataset to Advance Precision Medicine

Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

Home
/
update
/
details

Illumina Launches Pilot Proteomics Program with UK Biobank and Industry Partners

NextEdge Admin

13 Jan 2025

2 min 37 sec

Illumina, Inc. , a global leader in DNA sequencing, has launched a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The initiative will utilize Illumina Protein Prep™, an NGS-based proteomics assay powered by SOMAmer® technology, to enhance access to proteomic insights.

Proteomics offers a deeper understanding of cellular function, disease mechanisms, and biomarker discovery, particularly for conditions like cancer and cardiovascular disease. Protein quantitative trait loci (pQTLs) are emerging as key proteogenomic tools, linking genetic variation to protein expression and disease phenotypes. Illumina Protein Prep aims to accelerate high-throughput proteomics research.

"UK Biobank data is a cornerstone for the omics community, and we're thrilled to collaborate across the industry as we prepare to launch Illumina Protein Prep," said Steve Barnard, PhD, Illumina’s chief technology officer. "This pilot will generate high-quality NGS-based proteomics data to drive new biological insights."

UK Biobank will supply 50,000 samples from participants also included in its Pharma Proteomics Project. deCODE Genetics will process these using the Illumina Protein Prep solution and NovaSeq™ X Plus system, with analysis via the DRAGEN Protein Quantification pipeline. The first 30,000 samples, co-funded by Illumina, deCODE Genetics, and Standard BioTools, will be released to the research community in late 2025. The remaining 20,000 will have a temporary industry-exclusive period before public release.

Illumina Protein Prep detects 9,000 human proteins using 11,000 SOMAmer reagents. Currently in early access release, the assay detects 6,000 proteins and is compatible with NovaSeq systems. The full commercial launch is set for early 2025.